Cluster headache: what has changed since 1999?

Massimo Leone • Alberto Proietti Cecchini • Vincenzo Tullo • Marcella Curone
• Paola Di Fiore • Gennaro Bussone
Springer-Verlag Italia 2013

The peripheral and central origin of pain in cluster headache (CH) and trigeminal autonomic cephalalgias (TACs) has been matter of debate. In the last decade, a number of information came from both animal and human studies. This paper briefly highlights main data from these studies. Taken together, there is now sufficient body of evidence indicating that CH and TACs can be regarded as a unique headache spectrum–syndrome, due to involvement of specific brain areas.

Until 1988, cluster headache (CH) was classified together with migraine under the section of ‘‘vascular headaches’’ [1]. For the first time in 1988 the International headache society (IHS) classification separated CH from migraine [2]. In the second IHS classification [2] CH was grouped together with other two primary headache forms: paroxysmal hemicrania (PH), and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) [3]. This group was named the trigeminal autonomic cephalalgias (TACs) and is characterised by attacks of unilateral head pain associated with ipsilateral craniofacial autonomic manifestations. Attack duration is the main feature that distinguishes the three TAC forms.

The term TAC was first introduced by Goadsby and Lipton [4] in 1997 because of the simultaneous activation of trigeminal and parasympathetic craniofacial nerves both in these headache forms. The contemporary activation of these nerves could be due to pathological activation of the trigeminofacial brainstem reflex [4].

The peripheral and central origin of pain in TACs, mainly in CH has been matter of debate. Orbital phlebographies in CH and other headaches did not reveal differences and systemic signs of inflammation have never been reported in CH [5], thus excluding inflammation of the cavernous sinus as a source of the pain in CH.

Vasodilation seems not to be the cause of pain in CH:
Intracranial vasodilation is not specific to CH as it is observed in experimental forehead pain [6]. In addition, CH can occur even if vasodilation is blocked by trigeminal nerve section [7].

Sumatriptan efficacy is due to the antagonistic effect on peripheral 5-HT1D (at trigeminal nerve endings) and 5-HT1B receptors (on the walls of intracranial blood vessels) [8]
. Thanks to these effects on peripheral 5-HT1D and 5-HT1B receptors, sumatriptan could control CH pain by reducing the increased concentrations of calcitonin gene-related peptide in the ipsilateral jugular vein during CH attacks [9].

A peripheral origin of pain in CH and TACs also comes from secondary forms of these headaches: under such circumstances the clinical characteristics of CH and TACs are rather often difficult to differentiate the primary forms [10]. In many cases, the lesions are located in the sella turcica or the sinus cavernosus [10], and surgical removal leads to resolution of the pain.

Other observations indicate that activation of trigeminal nerve endings alone cannot explain the pain of CH (and other TACs). Other factors probably in the brain play a role in pain generation. Vasodilators such as alcohol, nitro-glycerine [11], and the 5-HT2B agonist m-chlorophenyl-piperazine [12], can precipitate CH attacks but only during the bouts. These observations point to a central permissive state allowing vasodilation being perceived as painful.

In a PET study, peripheral trigeminal activation occurs in CH [13] without provoking CH pain attacks; in addition, surgical lesioning of the trigeminal nerve does not always resolve the pain in CH as well as other TACs [14, 15].

It is of interest to note that sumatriptan retains its ability to stop CH attacks after complete trigeminal nerve section [7], indicating that its effect is not at peripheral level but in the brain.
Other data also suggest that the trigeminal nerve is not crucial in CH and TACs pain. In a large study on CH patients, 48 % reported the headache outside the trigeminal distribution [16]. In PH pain can occur in various non-trigeminal areas, occipital (42 %), neck (32 %), ear (13 %), ipsilateral shoulder (10 %), and arm (10 %) [17].

In SUNCT pain can occur in the back of the head and neck in 31 % and in the ear in 6 % [18]. The clockwork regularity of CH attacks and the seasonal recurrence of CH led to the hypothesis that a biological clock in the hypothalamus was involved in CH [11]. In the same direction go the observations that attacks can be provoked by napping [11], and the shift to their regular times after changing time zone [11].

Neuroendocrinological abnormalities have been documented in CH substantiating hypothalamic involvement in CH [19]. CH and TACs should be regarded as a syndrome, with a central component predominating in primary forms and a peripheral component predominating in secondary forms.

Neuroimaging findings, clinical characteristics and neuroendocrinological abnormalities in CH and in the other TACs pointed to a hypothalamic involvement, prompting the idea that this brain area could act cluster generator [20].
In animals, a direct connection between the posterior hypothalamus and the trigeminal nucleus caudalis through the trigemino-hypothalamic tract has been demonstrated [21].

Sensory information from trigeminally innervated territories is conveyed to the hypothalamus via the trigemino-hypothalamic tract [21]. On the contrary, stimulation of the posterior hypothalamus modulates the activity of trigeminal nucleus caudalis neurons: this effect is mediated by a number of substances, such as orexins [22}.

In a PET study conducted in patients with chronic CH under hypothalamic stimulation [13], hypothalamic stimulation induced activation in both the ipsilateral hypothalamic grey and the ipsilateral trigeminal system documenting for the first time a connection between the hypothalamus and the trigeminal system in humans. In this study, activation of the trigeminal nerve and ganglion did not produce any headache nor head sensation suggesting that trigeminal activation is not sufficient to fully explain CH pain [13].

Taking together data from animals and humans, there is now sufficient body of evidence indicating that the posterior hypothalamus plays a role in head pain modulation.

High-frequency hypothalamic stimulation to treat chronic drug-resistant CH was introduced in 2000 to inhibit hyperactivity of this brain area previously detected by PET [23]. So far, experience from more than 60 patients with drug resistant chronic CH treated with hypothalamic stimulation shows a remarkable improvement in about 60 % of cases [24]. Hypothalamic stimulation is also effective in SUNCT [25–27] and in PH [28]. Acute stimulation does not improve ongoing CH attacks [29], and stimulation must continue for weeks or months before there is benefit [30].

Taken together, these observations suggest that the mechanism of action of hypothalamic stimulation is not the mere result of inhibition of hypothalamic neurons [30]. The increased threshold for cold pain in first trigeminal branch on the stimulated side in patients under chronic hypothalamic stimulation suggested modulation of the antinociceptive system [31].

Hypothalamic stimulation affects major pain-matrix areas: activation has been recorded in the thalamus, somatosensory cortex, precuneus, and anterior cingulate cortex, whereas deactivation occurs in the middle temporal gyrus, posterior cingulate cortex, and insula [13]. This suggests that it restores normal function of pain network in CH patients. The original hypothesis that the hypothalamus is the so-called CH generator was appealing, but recent neuroimaging findings and the accumulated experience with hypothalamic stimulation indicate other interpretations.

If the posterior hypothalamus was the CH generator, one would expect hypothalamic stimulation to trigger CH pain attacks, but this is not the case [30]. An alternative explanation about the role of the posterior hypothalamus in CH and TACs is that its activation leads to attack termination, thus regulating the duration of an attack [32]; this ability could explain the different attack durations in the various TAC forms.

Data accumulated in the last years, led to move beyond the search of a single trigger zone as previously thought in CH. Brain areas involved in a CH attack [20] are almost the same of those traditionally regarded as the pain matrix; moreover, these areas show a huge overlap with brain areas modified by hypothalamic stimulation [13].

These areas play a major role also in autonomic, cognitive and affective functions. A derangement in one or more of these areas, or alternatively a deficit in their interactions, could be the cause of a permissive state leading to disinhibition of the hypothalamo-trigeminal pathway that in turn may start a pain attack.

Conflict of interest
We certify that there is no actual or potential conflict of interest in relation to this article.

1. Ad Hoc Committee on Classification of Headache (1962) Clas-
sification of headache. JAMA 179(9):717–718

2. Headache Classification Committee of the International Head-
ache Society (1988) Classification and diagnostic criteria for
headache disorders, cranial neuralgias and facial pain. Cepha-
lalgia 8(Suppl 7)

3. Headache Classification Subcommittee of the International
Headache Society (2004) The international classification of
headache disorders: 2nd edn. Cephalalgia 24(Suppl 1):1–160

4. Goadsby PJ, Lipton RB (1997) A review of paroxysmal hemi-
cranias, SUNCT syndrome and other shortlasting headaches with
autonomic feature, including new cases. Brain 120:193–209

5. Nilsson Remahl I, Waldenlind E, Bratt J, Ekbom K (2000)
Cluster headache is not associated with signs of a systemic
inflammation. Headache 40:276–281

6. May A, Buchel C, Turner R, Goadsby PJ (2001) Magnetic res-
onance angiography in facial and other pain: neurovascular
mechanisms of trigeminal sensation. J Cereb Blood Flow Metab

7. Matharu MS, Goadsby PJ (2002) Persistence of attacks of cluster
headache after trigeminal nerve root section. Brain 125:976–984

8. Moskowitz MA (1990) Basic mechanisms in vascular headache.
Neurol Clin 8:801–815

9. Goadsby PJ, Edvinsson L (1994) Human in vivo evidence for
trigeminovascular activation in cluster headache. Neuropeptide
changes and effects of acute attacks therapies. Brain 117:427–434

10. Favier I, van Vliet JA, Roon KI et al (2007) Trigeminal auto-
nomic cephalgias due to structural lesions: a review of 31 cases.
Arch Neurol 64:25–31

11. Kudrow L (1980) Cluster headache, mechanism and manage-
ment, 1st edn. Oxford University Press, New York

12. Leone M, Attanasio A, Croci D et al (1997) The
m-chlorophe- nylpiperazine test in cluster headache: a study on central serotoninergic activity. Cephalalgia 17:666–672

13. May A, Leone M, Boecker H et al (2006) Hypothalamic deep
brain stimulation in positron emission tomography. J Neurosci

14. Jarrar RG, Black DF, Dodick DW, Davis DH (2003) Outcome of
trigeminal nerve section in the treatment of chronic cluster
headache. Neurology 60:1360–1362

15. Black DF, Dodick DW (2002) Two cases of medically and sur-
gically intractable SUNCT: a reason for caution and an argument
for a central mechanism. Cephalalgia 22:201–204

16. Torelli P, Cologno D, Cademartiri C, Manzoni GC (2001)
Application of the International Headache Society classification
criteria in 652 cluster headache patients. Cephalalgia 21:145–150

17. Cittadini E, Matharu MS, Goadsby PJ (2008) Paroxysmal hemi-
crania: a prospective clinical study of 31 cases. Brain

18. Cohen AS, Matharu MS, Goadsby PJ (2006) Short-lasting uni-
lateral neuralgiform headache attacks with conjunctival injection
and tearing (SUNCT) or cranial autonomic features (SUNA)—a
prospective clinical study of SUNCT and SUNA. Brain

19. Leone M, Bussone G (1993) A review of hormonal findings in
cluster headache. Evidence for hypothalamic involvement.
Cephalalgia 13:309–317

20. May A, Bahra A, Buchel C, Frackowiak RS, Goadsby PJ (1998)
Hypothalamic activation in cluster headache attacks. Lancet

21. Malick A, Strassman AM, Burstein R (2000) Trigeminohypo-
thalamic and reticulohypothalamic tract neurons in the upper
cervical spinal cord and caudal medulla of the rat. J Neurophysiol

22. Bartsch T, Levy MJ, Knight YE, Goadsby PJ (2004) Differential
modulation of nociceptive dural input to [hypocretin] orexin A
and B receptor activation in the posterior hypothalamic area. Pain

23. Leone M, Franzini A, Bussone G (2001) Stereotactic stimulation
of posterior hypothalamic gray matter for intractable cluster
headache. N Engl J Med 345:1428–1429

24. Magis D, Schoenen J (2012) Advances and challenges in neur-
ostimulation for headaches. Lancet Neurol 11(8):708–719

25. Leone M, Franzini A, D’Andrea G, Broggi G, Casucci G, Bus-
sone G (2005) Deep brain stimulation to relieve severe drug-
resistant SUNCT. Ann Neurol 57:924–927

26. Lyons MK, Dodick DW, Evidente VG (2008) Responsiveness of
short-lasting unilateral neuralgiform headache with conjunctival
injection and tearing to hypothalamic deep brain stimulation.
J Neurosurg 26:1–3

27. Bartsch T, Falk D, Knudsen K, Reese R, Raethjen J, Mehdorn
HM et al (2011) Deep brain stimulation of the posterior hypo-
thalamic area in intractable short-lasting unilateral neuralgiform
headache with conjunctival injection and tearing (SUNCT).
Cephalalgia 31(13):1405–1408

28. Walcott BP, Bamber NI, Anderson DE (2009) Successful treat-
ment of chronic paroxysmal hemicrania with posterior hypotha-
lamic stimulation: technical case report. Neurosurgery 65:E997
(discussion E997)

29. Leone M, Franzini A, Broggi G, Mea E, Proietti Cecchini A,
Bussone G (2006) Acute hypothalamic stimulation and ongoing
cluster headache attacks. Neurology 67:1844–1845

30. Leone M, Franzini A, Proietti Cecchini A, Bussone G (2013)
Success, failure and putative mechanisms in hypothalamic stim-
ulation for drug-resistant chronic cluster headache. Pain

31. Jurgens T, Leone M, Proietti-Cecchini A, Busch V, Mea E,
Bussone G, May G (2009) Hypothalamic deep-brain stimulation
modulates thermal sensitivity and pain thresholds in cluster
headache. Pain 146(1–2):84–90

32. May A (2005) Cluster headache: pathogenesis, diagnosis, and
management. Lancet 366:843–855
Neurol Sci (2013) 34 (Suppl 1):S71–S73
0 people like this